Centene rises 3.2% as healthcare sector strength lifts shares

What happened

Centene (CNC) rose 3.2% to $70.81 on October 20, 2026, largely moving with a healthcare sector that rose 3.0% as Ambetter Health product updates and a scheduled earnings release provided background. PRNewsWire reported Ambetter Health disclosed its 2027 Marketplace offerings that add new heart failure coverage and expand chronic care solutions across nine states, and PRNewsWire also noted Centene scheduled its 2026 third quarter financial results for October 27, 2026. GuruFocus reported the stock closed 0.6% below a 52-week high of $71.21 that day.

How big was the move

The stock’s daily change was 1.5 times a typical daily move for this stock, and it rose 2.8% over the last five sessions. Trading volume was 0.8 times its 20-day average. The S&P 500 rose 0.3% on the day while the S&P 500 over five sessions fell 1.2%. Compared with its sector, the stock’s move was 0.2 percentage points better than the sector median. The company’s market sensitivity is captured by a beta of 0.34, indicating the stock tends to move less than the market. Overall, this appeared largely a sector-wide move, with company news serving as background.

The technical picture

The stock was 8.5% above its 20-day moving average, 8.0% above its 50-day moving average, and 30.1% above its 200-day average. The 50-day average is above the 200-day average, a sign of an established uptrend, and the stock had spent 136 consecutive trading days above the 200-day average. Its Relative Strength Index (14 days) was 66 (between 30 and 70, a neutral range). Centene was 0.6% below its 52-week high. Over one month the stock rose 9.0% and over three months it rose 7.5%. Over one year it rose 100.8%, which was 85.0 percentage points ahead of the S&P 500. Volatility was 34% annualized over 60 days, higher than 56% of its own readings over five years.

Fundamentals and valuation

For the four quarters through June 30, 2026, Centene reported revenue of $193.73 billion, which grew 8.7% from a year earlier; revenue growth one quarter earlier was growth of 17.0%. Diluted earnings per share for that period were $-10.44, with earnings per share growth from a year earlier that fell 358.4%. Gross margin was 16.1% (a year earlier: 8.9%), operating margin was 2.8% (a year earlier: 1.1%), and free-cash-flow margin was 4.6%. Return on invested capital was 12.9%. The balance sheet showed net cash of $8.05 billion, and share count over one year increased by 0.8%.

Valuation measures included price to forward earnings of 14.5 times expected earnings and a free-cash-flow yield of 26.2%. PromtFinance scores placed the company high for Momentum at 98 (Exceptional) and strong for Stability at 87 (Strong), while Growth was 39 (Weak) and Quality 51 (Neutral). Those mixed fundamentals alongside elevated momentum frame how investors might weigh short-term technical strength against longer-term earnings and margin trends.

Earnings and analyst expectations

Centene’s next report was scheduled for October 27, 2026. The last report, on July 28, 2026, delivered earnings per share of $2.51 against $1.09 expected, 130.3% above estimates. The company had recorded four consecutive quarters beating estimates, with an average surprise over the last four reports of 100.0% above estimates. The typical two-day reaction after recent reports was the stock rose 2.6%.

Analysts’ consensus price target was $68.29, which was 3.6% below the closing price, based on 44 analysts with a consensus rating of Buy and 61% of ratings at Buy or Strong Buy. Investors will watch the October 27 report for how revenue, margins and cash flow progress after recent beats and amid product and marketplace changes announced by Ambetter Health.

What to watch

• October 27, 2026: Centene scheduled to release its 2026 third quarter financial results at about 6:00 a.m. ET and host a conference call at 8:30 a.m. ET.
• Ambetter Health 2027 Marketplace offerings: added heart failure coverage and expanded chronic care solutions across nine states (PRNewsWire).
• Technical proximity to the 52-week high: the stock is 0.6% below its 52-week high of $71.21.
• Valuation and fundamentals to watch in the report: price to forward earnings 14.5 times expected earnings and free-cash-flow yield 26.2%.
• Shareholder metrics ahead of the report: market value $34.16 billion and net cash of $8.05 billion.